The publication describes the discovery of a novel series of Imidazopyrazine derivatives by IRBM’s drug discovery team. This novel series of SHP2 allosteric inhibitors, having an imidazopyrazine 6,5-fused heterocyclic system as central scaffold, showed an excellent potency in enzyme and cellular assays.
New IRBM Contribution to Pharmaceutics Journal
We are delighted that positive outcomes of our contribution to the “Magic Bullet” project developed under the Marie Skłodowska-Curie Actions research fellowship program are being recognized. One important example is this recently published paper in Pharmaceutics that we co-authored.
The study focused on the synthesis and evaluation of multiple RGD-cryptophycin conjugates for targeted delivery to treat multi-drug resistant cancer cells. These small molecule drug conjugates were comprehensively assessed for stability, anti-proliferative effects, selectivity and drug delivery. The results of these evaluations enabled the research team to conclude that there are exciting future opportunities in the design of novel cryptophycin-based therapeutic agents.